HHGA
LFCR icon

Halbert Hargrove Global Advisors’s Lifecore Biomedical LFCR Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-230
Closed -$1.69K – 579
2025
Q3 		$1.69K Buy
+230
New +$1.74K ﹤0.01% 600

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $143M AUM 6.82% 1-Year Est. Return

Halbert Hargrove Global Advisors's LFCR Position: Q4 2025 in Review

Halbert Hargrove Global Advisors sold out of Lifecore Biomedical (LFCR) in Q4 2025, closing a stake of 230 shares — an estimated $1.69K sold.

Halbert Hargrove Global Advisors first reported a position in LFCR in Q3 2025 and held it in 1 quarter. The position peaked at $1.69K in Q3 2025. 104 funds tracked by Wall St. Rank hold LFCR as of Q4 2025.

  • Halbert Hargrove Global Advisors reported no remaining Lifecore Biomedical position as of Q4 2025 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 230 Lifecore Biomedical shares in Q4 2025, an estimated $1.69K.
  • Halbert Hargrove Global Advisors first reported a position in Lifecore Biomedical in Q3 2025 and held it in 1 quarter.
  • Halbert Hargrove Global Advisors's Lifecore Biomedical position peaked at $1.69K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2025.

Based on Halbert Hargrove Global Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.